COMPASS PATHWAYS PLC Proceeds from Common Stock Issued
COMPASS PATHWAYS PLC (CMPS) reported Proceeds from Common Stock Issued of $140.64 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-05-13
- COMPASS PATHWAYS PLC proceeds from issuance of common stock for the quarter ending 2026-03-31 was $140.64M, a 0.20% increase year-over-year.
- COMPASS PATHWAYS PLC proceeds from issuance of common stock for the quarter ending 2025-12-31 was $0.00.
- COMPASS PATHWAYS PLC proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00.
- COMPASS PATHWAYS PLC proceeds from issuance of common stock for the quarter ending 2025-06-30 was $0.00.
- COMPASS PATHWAYS PLC proceeds from issuance of common stock for fiscal 2025 was $140.36M, a 435.33% increase from fiscal 2024.
- COMPASS PATHWAYS PLC proceeds from issuance of common stock for fiscal 2024 was $26.22M, a 81.91% decline from fiscal 2023.
- COMPASS PATHWAYS PLC proceeds from issuance of common stock for fiscal 2023 was $144.94M, a 32839.77% increase from fiscal 2022.
- COMPASS PATHWAYS PLC proceeds from issuance of common stock for fiscal 2022 was $440.00K, a 99.72% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2026-03-31 | $140.64M 10-Q · filed 2026-05-13 | $140.64M derived: sum of 2 quarters · filed 2026-05-13 | $140.64M derived: sum of 3 quarters · filed 2026-05-13 | $140.64M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $0.00 derived: sum of 2 quarters · filed 2026-03-24 | $0.00 derived: sum of 3 quarters · filed 2026-03-24 | $140.36M 10-K · filed 2026-03-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $140.36M 10-Q · filed 2025-11-04 | $140.36M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $140.36M 10-Q · filed 2025-07-31 | $140.36M derived: sum of 3 quarters · filed 2026-05-13 | $140.36M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-03-31 | $140.36M 10-Q · filed 2026-05-13 | $140.36M derived: sum of 2 quarters · filed 2026-05-13 | $140.36M derived: sum of 3 quarters · filed 2026-05-13 | $140.36M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $0.00 derived: sum of 2 quarters · filed 2026-03-24 | $0.00 derived: sum of 3 quarters · filed 2026-03-24 | $26.22M 10-K · filed 2026-03-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $26.22M 10-Q · filed 2025-11-04 | $26.18M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $26.22M 10-Q · filed 2025-07-31 | $26.18M derived: sum of 3 quarters · filed 2025-07-31 | $143.03M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $26.22M 10-Q · filed 2025-05-08 | $26.18M derived: sum of 2 quarters · filed 2025-05-08 | $143.03M derived: sum of 3 quarters · filed 2025-05-08 | $169.97M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $116.81M derived: sum of 2 quarters · filed 2025-02-27 | $143.75M derived: sum of 3 quarters · filed 2025-02-27 | $144.94M 10-K · filed 2025-02-27 |
| 2023-09-30 | $116.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $143.79M derived: sum of 2 quarters · filed 2024-10-31 | $144.98M 10-Q · filed 2024-10-31 | $145.42M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $26.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $28.12M 10-Q · filed 2024-08-01 | $28.56M derived: sum of 3 quarters · filed 2024-08-01 | $28.56M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $1.19M 10-Q · filed 2024-05-08 | $1.63M derived: sum of 2 quarters · filed 2024-05-08 | $1.63M derived: sum of 3 quarters · filed 2024-05-08 | $1.63M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $440.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $440.00K derived: sum of 2 quarters · filed 2024-02-29 | $440.00K derived: sum of 3 quarters · filed 2024-02-29 | $440.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $154.79M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $154.79M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $154.79M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | -$132.82M derived: 10-K 12 month − 6-K 9 month · filed 2023-02-28 | -$55.97M derived: sum of 2 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2020-09-30 | $76.85M derived: 6-K 9 month − 6-K 6 month · filed 2021-11-09 | $132.82M 6-K · filed 2021-11-09 | ||
| 2020-06-30 | $55.97M 6-K · filed 2021-08-11 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |